Stay Updated with the Latest BB Biotech AG BION.SW News in Real Time
Find BION.SW news now at Meyka AI. Stay informed with the latest BB Biotech AG stocks updates, including price news, market analysis, and expert insights.
Dassault Systèmes (EPA: DSY) Shares Rise After Q2 Earnings Beat and Up to $2 Billion ArisGlobal AI Deal
Dassault Systèmes reported solid Q2 2026 results on July 23, alongside a major acquisition announcement. The French software maker posted total revenue of €1.56 billion, up 4% in constant currency. Non-IFRS diluted EPS climbed 8% to €0.31, while operating margin expanded to 30%. Dassault Systèmes also unveiled a deal to acquire life sciences software firm…
Q32 Bio (NASDAQ: QTTB) Jumps 60% on Strong 36-Week Clinical Data for Hair Loss Treatment
On 13 July 2026, Q32 Bio (NASDAQ: QTTB) became one of the biggest gainers in the biotech sector after its shares climbed about 60% on the back of positive 36-week Phase 2a clinical results for its experimental alopecia areata treatment, bempikibart. The latest data showed meaningful hair regrowth in patients with severe hair loss while…
Abivax Shares Jump 3.91% After $920 Million Stock Offering Grows Beyond Expectations
Abivax shares climbed 3.91% on Nasdaq on July 2, 2026, after the French biotech confirmed its $920 million American Depositary Share offering. Underwriters exercised their full option, pushing gross proceeds well past the original $600 million target. The ADS offering priced at $125.00 apiece on July 1. Abivax (Nasdaq: ABVX, Euronext Paris: ABVX) said the…
AlzeCure Shares Soar 71% to Highest Since 2022 on $2.2 Billion Alzheimer’s Drug Licensing Deal
AlzeCure shares surged 71% on June 30, 2026, reaching their highest level since early 2022 after the Swedish biotech company announced an Alzheimer’s drug licensing agreement valued at more than $2.2 billion, excluding royalties. The deal gives global development and commercialization rights to its lead candidate, ACD856, and marks a major milestone for the company….
Abivax Shares Soar 27% After Ulcerative Colitis Drug Shows Strong Results in Hard-to-Treat Patients
Abivax shares surged sharply after new clinical trial results for its ulcerative colitis treatment, obefazimod, showed strong performance in patients who previously failed standard therapies. The stock reaction reflects renewed investor confidence in the biotech pipeline and growing hopes for a breakthrough therapy in a difficult disease area. The move also comes at a time…
Avience Biomedicals Ltd Share Price Jumps 90%: Stock Lists at ₹395.20 on NSE SME After IPO at ₹208
Avience Biomedicals Ltd (NSE SME: AVIENCE) delivered one of the standout SME debuts of 2026. The IPO was priced at ₹208 per share, with a price band of ₹196 to ₹208. On June 25, 2026, the stock listed at ₹395.20 on NSE SME Emerge, a gain of approximately 90% over the issue price. The debut…
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal, Offering Nearly 50% Premium
AbbVie made a major move in the biotech sector on June 22, 2026, announcing a $10.9 billion deal to acquire Apogee Therapeutics. The transaction offers Apogee shareholders nearly a 50% premium and gives AbbVie access to a promising pipeline of immunology treatments. As competition grows in the market for inflammatory disease therapies, this acquisition could…
Anthem Biosciences Sees ₹1,275 Crore Block Deal as Societe Generale, Prudential Buy 3% Stake
Anthem Biosciences just attracted serious global institutional attention. On June 19, 2026, the Bengaluru-based pharma services company saw a large block deal hit the National Stock Exchange. Global investors led by Societe Generale, Prudential Hong Kong, and Ghisallo Capital Management acquired a combined 3% stake in Anthem Biosciences from promoter Aruna Ganesh for ₹1,275 crore…
Analyst Upgrades and Downgrades Today: Focus Stocks AAPL, INTC, NFLX, AMD, OPAD, NVCT, TFPM
Wall Street does not stop moving. Every trading day, analysts at major firms review their positions on stocks and publish fresh rating actions. These analyst upgrades and downgrades directly influence how institutional and retail investors think about a stock. When a top firm shifts its stance on a name like Apple (AAPL) or Intel (INTC),…